Target intelligence / Profile preview

FK506 binding protein 3 pseudogene (FKBP3 pseudogene)

Target
FKBP3 pseudogene
Molecular classification
Other
01

Overview

The FK506 binding protein 3, 25kDa pseudogene (ENSG00000237922) is a genomic relic related to the FKBP3 gene but does not encode a functional protein. True FKBP3 is a peptidyl-prolyl cis-trans isomerase involved in protein folding, immunoregulation, and other cellular processes. However, this pseudogene does not participate in these processes or serve as a therapeutic target[5][1][3].

Other names
FKBP25 pseudogeneFKBP3-psimmunophilin 25kDa pseudogeneENSG00000237922
02

Mechanism of action

null

Beyond the preview

Go deeper on FK506 binding protein 3 pseudogene (FKBP3 pseudogene).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on FK506 binding protein 3 pseudogene (FKBP3 pseudogene).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call